Search Results - "Taylor, Douglas C. A."

Lessons learned: Chronic idiopathic constipation patient experiences with over-the-counter medications by Lacy, Brian E, Shea, Elizabeth P, Manuel, Machelle, Abel, Jessica L, Jiang, Hancheng, Taylor, Douglas C A

“…Chronic idiopathic constipation (CIC) is a prevalent functional gastrointestinal disorder diagnosed based on patient-reported symptoms and the absence of…”
Get full text

Alarming Trends in Opioid Use Among Patients With GERD by Howden, Colin W., Taylor, Douglas C.A., Tkacz, Joseph

“…Using cross-sectional, national data, they observed that approximately 10% of patients visiting a physician for a gastrointestinal condition were in receipt of…”
Get full text

Methods of Model Calibration: Observations from a Mathematical Model of Cervical Cancer by Taylor, Douglas C. A., Pawar, Vivek, Kruzikas, Denise, Gilmore, Kristen E., Pandya, Ankur, Iskandar, Rowan, Weinstein, Milton C.

“…Background : Mathematical models are commonly used to predict future benefits of new therapies or interventions in the healthcare setting. The reliability of…”
Get full text

Cost-Effectiveness of Intensive Atorvastatin Therapy in Secondary Cardiovascular Prevention in the United Kingdom, Spain, and Germany, Based on the Treating to New Targets Study by Taylor, Douglas C. A., Pandya, Ankur, Thompson, David, Chu, Paula, Graff, Jennifer, Shepherd, James, Wenger, Nanette, Greten, Heiner, Carmena, Rafael, Drummond, Michael, Weinstein, Milton C.

“…The Treating to New Targets (TNT) clinical trial found that intensive 80 mg atorvastatin (A80) treatment reduced cardiovascular events by 22% when compared to…”
Get full text

Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US by Rosen, Virginia M., Taylor, Douglas C. A., Parekh, Hemangi, Pandya, Ankur, Thompson, David, Kuznik, Andreas, Waters, David D., Drummond, Michael, Weinstein, Milton C.

“…Background : A recent study found fewer hospitalizations for congestive heart failure (CHF) patients receiving high-dose versus low-dose statin therapy…”
Get full text

Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer by Parthan, Anju, Pruttivarasin, Narin, Davies, Diane, Taylor, Douglas C A, Pawar, Vivek, Bijlani, Akash, Lich, Kristen Hassmiller, Chen, Ronald C

“…To determine the cost-effectiveness of several external beam radiation treatment modalities for the treatment of patients with localized prostate cancer. A…”
Get full text

Incorporating Calibrated Model Parameters into Sensitivity Analyses: Deterministic and Probabilistic Approaches by Taylor, Douglas, Pawar, Vivek, Kruzikas, Denise T., Gilmore, Kristen E., Sanon, Myrlene, Weinstein, Milton C.

“…Objective : The aim of this study was to examine how calibration uncertainty affects the overall uncertainty of a mathematical model and to evaluate potential…”
Get full text

Treatment for chronic idiopathic constipation: Use and satisfaction from a nationwide survey of US participants by Lacy, Brian E., Xu, Yanqing, Taylor, Douglas C. A., Kosch, Katherine J., Dobrescu, Rachel, Morlock, Amy, Morlock, Robert, Rooker, Ceciel

“…Background Chronic idiopathic constipation (CIC) is a disorder of gut–brain interaction characterized by a variety of bowel movement‐related and abdominal…”
Get full text

Burden of illness and treatment attitudes among participants meeting Rome IV criteria for irritable bowel syndrome: A nationwide survey in the United States by Lacy, Brian E., Xu, Yanqing, Taylor, Douglas C. A., Kosch, Katherine J., Dobrescu, Rachel, Morlock, Amy, Morlock, Robert, Rooker, Ceciel

“…Background Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction characterized by abdominal pain and altered bowel habits, with…”
Get full text

The Burden and Treatment of Chronic Constipation Among US Nursing Home Residents by Zhang, Tingting, Zullo, Andrew R., James, Hannah O., Lee, Yoojin, Taylor, Douglas C.A., Daiello, Lori A.

“…To evaluate the burden of chronic constipation (CC) and the use of drugs to treat constipation (DTC) in 2 complementary data sources. Retrospective cohort…”
Get full text

The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study by Taylor, Douglas C.A, Abel, Jessica L, Doshi, Jalpa A, Martin, Carolyn, Goolsby Hunter, Alyssa, Essoi, Breanna, Korrer, Stephanie, Reasner, David S, Carson, Robyn T, Chey, William D

“…GOALS:This study aimed to characterize the impact of stool consistency on patient-reported bowel movement (BM) satisfaction in patients with irritable bowel…”
Get full text

S656 Burden of Anal/Rectal-Related Adverse Consequences Associated with Chronic Straining Among Patients with Irritable Bowel Syndrome And/Or Constipation by Taylor, Douglas CA, Xu, Yanqing, Kosch, Katherine J., Liang, Yi, Tran, Phuong T., Simrén, Magnus, Chey, William D.

Get full text

S513 Disease Burden and Care-Seeking Behavior for CIC Patients in the United States in the Era of COVID-19 by Lacy, Brian E., Taylor, Douglas CA, Morlock, Amy, Morlock, Robert, Rooker, Ceciel

Get full text

Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses by Hill, Gregory, Barron, Richard, Fust, Kelly, Skornicki, Michelle E, Taylor, Douglas C A, Weinstein, Milton C, Lyman, Gary H

“…Evaluate the cost-effectiveness of primary vs secondary prophylaxis (PP vs SP) with pegfilgrastim to reduce the risk of febrile neutropenia (FN) in…”
Get more information

S512 Prevalence and Impact of Abdominal Symptoms in Patients With IBS-C by Lacy, Brian E., Parikh, Mousam, Taylor, Douglas CA, Bloudek, Lisa, Burslem, Kate, Morlock, Amy, Morlock, Robert, Rooker, Ceciel

Get full text

Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy? by Clements, Karen M., Peltz, Gerson, Faries, Douglas E., Lang, Kathleen, Nyambose, Joshua, Earle, Craig C., Sugarman, Katherine P., Taylor, Douglas C. A., Thompson, David, Marciniak, Martin D.

“…Chemotherapy regimens may have differential efficacy by histology in nonsmall cell lung cancer (NSCLC). We examined the impact of histology on survival of…”
Get full text

Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States by Huang, Huan, Taylor, Douglas C A, Carson, Robyn T, Sarocco, Phil, Friedman, Mark, Munsell, Michael, Blum, Steven I, Menzin, Joseph

“…To use techniques of decision-analytic modeling to evaluate the effectiveness and costs of linaclotide vs lubiprostone in the treatment of adult patients with…”
Get more information

Calibrating Longitudinal Models to Cross-Sectional Data: The Effect of Temporal Changes in Health Practices by Taylor, Douglas C.A., MBA, Pawar, Vivek, PhD, Kruzikas, Denise, PhD, Gilmore, Kristen E., BA, Pandya, Ankur, MPH, Iskandar, Rowan, MA, Weinstein, Milton C., PhD

“…Abstract Objectives To assess the impact of simulating temporal changes in health-care practice patterns when calibrating longitudinal models to…”
Get full text

Epidemiology, survival, and costs of localized gastrointestinal stromal tumors by Rubin, Jaime L, Sanon, Myrlene, Taylor, Douglas Ca, Coombs, John, Bollu, Vamsi, Sirulnik, Leonardo

“…The aim of this study is to examine the epidemiologic and economic burden in surgically resected localized gastrointestinal stromal tumor (GIST) patients…”
Get full text

Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer by Thompson, David, PhD, Taylor, Douglas C.A., MBA, Montoya, Eduardo L., BA, Winer, Eric P., MD, Jones, Stephen E., MD, Weinstein, Milton C., PhD

“…Abstract Objective Data from the Intergroup Exemestane Study (IES) suggest that switching to the aromatase inhibitor, exemestane, after 2 to 3 years of…”
Get full text